Oncologica is a leading contract research organization specializing in small and large end-to-end bioinformatic CRO laboratory services. We offer bioanalytical clinical contract research to aid drug and targeted medicine innovation through our expertise in genetic cell-based assays, molecular biomarkers and immunogenicity services.
We work as a collaborative CRO partner to deliver integrated bioanalytical contract research solutions for your genomic sequencing needs. We excel in bioinformatics contract research where extensive sequencing capabilities and accurate detection of variants are required.
- Human genetics research partner
- Outsource genetic studies
- Bioanalytical pre-clinical contract research
- Drug manufacturing bioanalytical research
- UK based genetic CRO
Genomic Sequencing Services
Oncologica sequencing capabilities are suitable for:
- Rare disease studies
- Cancer exome analysis
- Complex disease genomics
- Translational research
RNA Sequencing Services
Our highly experienced bioinformatics team utilise lab sequencing and a leading genomic data library, for analysis and interpretation of:
- Gene expression
- Transcriptome analysis
- RNA sequencing services
Sequencing for the Microbiome
Our wide range sequencing capabilities allows our researchers to sequence all given genomic DNA in a complex sample. This provides valuable insights into community biodiversity and function. The sequencing data can be used for metagenomic assembly, function and gene resistance profiling.
Bacterial RNA Sequencing
Oncologica Sequencing provides bacterial RNA sequencing, which can identify and compare bacterial community in a sample by sequencing regions of the bacterial 16s rRNA gene.
- Access Oncologica’s large database of genomic data
- Undertake bioinformatic analysis for taxonomy assignment
Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer
J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33664-0. doi: https://doi.org/10.1016/j.jtho.2019.11.010.
Williams GH, Nicholson AG, Snead DRJ, Thunnissen E, Lantuejoul S, Cane P, Kerr KM, Loddo M, Scott MLJ, Scorer PW, Barker C. (2019)
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
David Jonathan Duncan ,Marietta Scott,Paul Scorer et al ()
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
Mod Pathol. 2019 Sep 26. doi: https://doi.org/10.1038/s41379-019-0372-z. [Epub ahead of print] Erratum in: Mod Pathol. 2019 Oct
Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, McCall EJ, Schimpl M, DeVries E, Walker J, Williams GH, Hunt J, Barker C. (2019)
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome
Br J Haematol. 2018 May;181(4):486-494. doi: https://doi.org/10.1111/bjh.15211. Epub 2018 Apr 20.
Sellar RS, Gale RE, Khwaja A, Garbowski M, Loddo M, Stoeber K, Williams GH, Linch DC
DNA replication licensing factor MCM2, geminin, and Ki67 define proliferative state and are linked with survival in oral squamous cell carcinoma
Eur J Oral Sci. 2018 Jun;126(3):186-196. doi: https://doi.org/10.1111/eos.12420.
Al-Hazmi N, Alhazzazi T, Williams G, Stoeber K, Al-Dabbagh R
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
Diagnostic Pathology, (2018) 13:47 DOI: https://doi.org/10.1186/s13000-018-0725-9
Paul Scorer, Marietta Scott, Nicola Lawson et al (2018)